Skip to Content

Natera Inc NTRA

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Natera Inc is operative in the healthcare field in the United States. Its core business is to offer invasive and other means of diagnosing genetic features of a fetus. Natera's array of diagnostic services include Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by studying the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother's blood and a blood sample from the alleged father. The Company acquires its revenue by billing an insurance carrier, a clinic or a patient for the test upon delivery of the test result.

Contact
201 Industrial Road, Suite 410
San Carlos, CA, 94070
T +1 650 249-9090
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Mar 31, 2020
Fiscal Year End Dec 31, 2020
Stock Type Speculative Growth
Employees 1,039